WallStSmart
EVMN

Evommune, Inc.

NYSE: EVMN · HEALTHCARE · BIOTECHNOLOGY

$23.29
-10.60% today

Updated 2026-06-02

Market cap
$717.49M
P/E ratio
P/S ratio
71.75x
EPS (TTM)
$-2.11
Dividend yield
52W range
$14 – $33
Volume
0.3M

Evommune, Inc. (EVMN) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item202320242025
Revenue$5.00M$7.00M$13.00M
Revenue growth (YoY)+40.0%+85.7%
Cost of revenue$1.00M$1.29M$1.39M
Gross profit$4.00M$5.71M$13.00M
Gross margin80.0%81.6%100.0%
R&D$32.00M$64.24M$74.04M
SG&A$20.03M
Operating income$-37.85M$-70.01M$-81.07M
Operating margin-757.0%-1000.2%-623.6%
EBITDA$-32.99M$-65.49M$-79.68M
EBITDA margin-659.9%-935.5%-612.9%
EBIT$-33.99M$-66.77M$-81.07M
Interest expense$58000.00$34000.00$7000.00
Income tax
Effective tax rate0.0%0.0%0.0%
Net income$-34.05M$-66.81M$-68.87M
Net income growth (YoY)-96.2%-3.1%
Profit margin-681.1%-954.4%-529.8%

Frequently asked questions

What is Evommune, Inc.'s revenue?

Evommune, Inc.'s trailing twelve-month revenue is $10.00M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is EVMN?

In its most recent fiscal year, EVMN ran a gross margin of 100.00%, an operating margin of -623.62%, and a net margin of -529.77%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does EVMN generate?

EVMN produced $-76.68M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is EVMN's balance sheet healthy?

EVMN holds $44.06M in cash and equivalents against — in long-term debt, on $205.57M of shareholder equity. That debt is best read against the cash flow the business throws off each year.